{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:57:37Z","timestamp":1793275057990,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["219497"],"award-info":[{"award-number":["219497"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-acting injectable PrEP (LAI-PrEP) provides opportunities to expand HIV prevention coverage in the Netherlands. Understanding which Dutch gay, bisexual and other men who have sex with men (GBMSM) are interested in using LAI-PrEP when available can support HIV prevention efforts. Survey data was collected online via the PROTECT survey from 1,447 GBMSM in the Netherlands between October 2023 and March 2024. Multivariable logistic analysis was conducted to determine variables associated with GBMSM who intend to use LAI-PrEP when available. Interest and intention to use LAI-PrEP among Dutch GBMSM is high (76.1% and 73.9%) and among those currently on oral PrEP even higher (80.8% and 79.5%). GBMSM who intend to use LAI-PrEP have more sexual partners in the past 6 months (11\u201350 partners (aOR\u2009=\u20093.24; 95%CI: 1.54\u20136.85), 51\u2013100 partners (aOR\u2009=\u20093.10; 95% CI: 1.20 to 8.30), more than 150 partners (aOR\u2009=\u20093.86; 95% CI: 1.74 to 8.67)), engage more in chemsex (aOR\u2009=\u20091.41; 95% CI: 1.00 to 2.01), are less likely to fear LAI-PrEP side effects (aOR\u2009=\u20090.83; 95% CI: 0.74 to 0.94;) or injection pain (aOR\u2009=\u20090.68; 95% CI: 0.61 to 0.75) and more likely to believe they are at risk of acquiring HIV (aOR\u2009=\u20091.23; 95% CI: 1.05 to 1.45). If made available in the Netherlands, many GBMSM are likely to commence using LAI-PrEP, particularly current oral PrEP users or discontinued users. Sexually active Dutch GBMSM, who are already protecting themselves, may be the first group to use LAI-PrEP.<\/jats:p>","DOI":"10.1007\/s10461-026-05038-0","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:52:02Z","timestamp":1769233922000},"page":"2129-2139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploring the Interest and Intention to Use Long-Acting Injectable PrEP (LAI-PrEP) Among Gay, Bisexual and Other Men Who Have Sex with Men (GBMSM) in the Netherlands"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-1823","authenticated-orcid":false,"given":"Johann","family":"Kolstee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama","family":"Appiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Milinkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"5038_CR1","unstructured":"UNAIDS. The path that ends AIDS: UNAIDS global AIDS update 2023. Geneva; 2023."},{"key":"5038_CR2","volume-title":"HIV prevention 2025 - Road map: getting on track to end AIDS as a public health threat by 2030","author":"UNAIDS","year":"2022","unstructured":"UNAIDS. HIV prevention 2025 - Road map: getting on track to end AIDS as a public health threat by 2030. Geneva: Joint United Nations Programme on HIV\/AIDS; 2022."},{"issue":"27","key":"5038_CR3","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"5038_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"5038_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"9883","key":"5038_CR6","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390.","journal-title":"Lancet"},{"issue":"4","key":"5038_CR7","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254\u201368.","journal-title":"Lancet HIV"},{"key":"5038_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-018-3463-4","volume":"18","author":"D Sidebottom","year":"2018","unstructured":"Sidebottom D, Ekstr\u00f6m AM, Str\u00f6mdahl S. A systematic review of adherence to oral pre-exposure prophylaxis for HIV\u2013how can we improve uptake and adherence? BMC Infect Dis. 2018;18:1\u201314.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"5038_CR9","first-page":"e20210963","volume":"76","author":"M Antonini","year":"2023","unstructured":"Antonini M, Silva IEd, Elias HC, Gerin L, Oliveira AC, Reis RK. Barriers to Pre-exposure prophylaxis (PrEP) use for HIV: an integrative review. Rev Bras Enferm. 2023;76(3):e20210963.","journal-title":"Rev Bras Enferm"},{"issue":"6","key":"5038_CR10","doi-asserted-by":"publisher","first-page":"e26516","DOI":"10.1002\/jia2.26516","volume":"28","author":"H Wang","year":"2025","unstructured":"Wang H, Popping S, van de Vijver D, Jonas KJ. Epidemiological impact and cost-effectiveness analysis of PrEP provision expansion among MSM in the Netherlands. J Int AIDS Soc. 2025;28(6):e26516.","journal-title":"J Int AIDS Soc"},{"key":"5038_CR11","volume-title":"The urgency of now: AIDS at a crossroads","author":"UNAIDS","year":"2024","unstructured":"UNAIDS. The urgency of now: AIDS at a crossroads. Geneva: Joint United Nations Programme on HIV\/AIDS; 2024."},{"issue":"1","key":"5038_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16382-4","volume":"23","author":"BG Rogers","year":"2023","unstructured":"Rogers BG, Chan P, Sutten-Coats C, Zanowick-Marr A, Patel R, Mena L, et al. Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States. BMC Public Health. 2023;23(1):1643.","journal-title":"BMC Public Health"},{"key":"5038_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/10497323241265943","author":"AR Gordon","year":"2024","unstructured":"Gordon AR, Haiken S, Murchison GR, Ag\u00e9nor M, Hughto JM, Nelson KM. Long-acting injectable pre-exposure prophylaxis perceptions and preferences among transgender and nonbinary young adults in the United States. Qual Health Res. 2024. https:\/\/doi.org\/10.1177\/10497323241265943.","journal-title":"Qual Health Res"},{"key":"5038_CR14","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1007\/s10461-017-2017-x","volume":"22","author":"D Kerrigan","year":"2018","unstructured":"Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, et al. Expanding the menu of HIV prevention options: a qualitative study of experiences with long-acting injectable cabotegravir as PrEP in the context of a phase II trial in the united States. AIDS Behav. 2018;22:3540\u20139.","journal-title":"AIDS Behav"},{"issue":"3","key":"5038_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25105","volume":"21","author":"E Hoornenborg","year":"2018","unstructured":"Hoornenborg E, Achterbergh RC, van der Loeff MFS, Davidovich U, van der Helm JJ, Hogewoning A, et al. Men who have sex with men more often chose daily than event-driven use of pre\u2010exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25105.","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"5038_CR16","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1007\/s10461-022-03693-7","volume":"26","author":"LC Krist","year":"2022","unstructured":"Krist LC, Zimmermann HM, van Dijk M, Stutterheim SE, Jonas KJ. PrEP use in times of COVID-19 in the Netherlands: men who have sex with men (MSM) on PrEP test less for HIV and renal functioning during a COVID-19 related lockdown. AIDS Behav. 2022;26(11):3656\u201366.","journal-title":"AIDS Behav"},{"key":"5038_CR17","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1007\/s10461-021-03200-4","volume":"25","author":"M van Dijk","year":"2021","unstructured":"van Dijk M, de Wit JB, Guadamuz TE, Martinez JE, Jonas KJ. Slow uptake of PrEP: behavioral predictors and the influence of price on PrEP uptake among MSM with a high interest in PrEP. AIDS Behav. 2021;25:2382\u201390.","journal-title":"AIDS Behav"},{"issue":"10","key":"5038_CR18","first-page":"e25389","volume":"22","author":"HM Zimmermann","year":"2019","unstructured":"Zimmermann HM, Eekman SW, Achterbergh RC, van der Loeff MFS, Prins M, de Vries HJ, et al. Motives for choosing, switching and stopping daily or event-driven pre\u2010exposure prophylaxis\u2013a qualitative analysis. Afr J Reprod Gynaecol Endoscopy. 2019;22(10):e25389.","journal-title":"Afr J Reprod Gynaecol Endoscopy"},{"issue":"8","key":"5038_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/QAD.0000000000000639","volume":"29","author":"JP Bil","year":"2015","unstructured":"Bil JP, Davidovich U, van der Veldt WM, Prins M, de Vries HJ, Sonder GJ, et al. What do Dutch MSM think of preexposure prophylaxis to prevent HIV-infection? A cross-sectional study. Aids. 2015;29(8):955\u201364.","journal-title":"Aids"},{"issue":"6","key":"5038_CR20","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s10508-019-01620-x","volume":"49","author":"M van Dijk","year":"2020","unstructured":"van Dijk M, Duken SB, Delabre RM, Stranz R, Schlegel V, Rojas Castro D, et al. PrEP interest among men who have sex with men in the Netherlands: covariates and differences across samples. Arch Sex Behav. 2020;49(6):2155\u201364.","journal-title":"Arch Sex Behav"},{"issue":"12","key":"5038_CR21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1080\/09540121.2015.1069785","volume":"27","author":"E Marra","year":"2015","unstructured":"Marra E, Hankins CA. Perceptions among Dutch men who have sex with men and their willingness to use rectal microbicides and oral pre-exposure prophylaxis to reduce HIV risk\u2013a preliminary study. AIDS Care. 2015;27(12):1493\u2013500.","journal-title":"AIDS Care"},{"key":"5038_CR22","doi-asserted-by":"crossref","unstructured":"Wang H, Zimmermann HM, van de Vijver D, Jonas KJ. Intention and preference to use long-acting injectable PrEP among MSM in the netherlands: a diffusion of innovation approach. AIDS Care. 2024:1\u201312.","DOI":"10.1080\/09540121.2024.2307378"},{"key":"5038_CR23","unstructured":"Philbin MM, Bergen S, Parish C, Kerrigan D, Kinnard EN, Reed S et al. Long-acting injectable ART and PrEP among women in six cities across the united states: a qualitative analysis of who would benefit the most. AIDS Behav. 2022:1\u201310."},{"issue":"3","key":"5038_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10900-023-01195-8","volume":"48","author":"K Paudel","year":"2023","unstructured":"Paudel K, Gupta S, Gautam K, Wickersham JA, Khati A, Azwa I, et al. High interest in long-acting injectable pre-exposure prophylaxis (LAI-PrEP) for HIV prevention among men who have sex with men (MSM): result from a nationwide survey in Malaysia. J Community Health. 2023;48(3):513\u201321.","journal-title":"J Community Health"},{"issue":"1","key":"5038_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10461-021-03344-3","volume":"26","author":"C Chan","year":"2022","unstructured":"Chan C, Vaccher S, Fraser D, Grulich AE, Holt M, Zablotska-Manos I, et al. Preferences for current and future PrEP modalities among PrEP-experienced gay and bisexual men in Australia. AIDS Behav. 2022;26(1):88\u201395.","journal-title":"AIDS Behav"},{"key":"5038_CR26","unstructured":"Keddem S, Thatipelli S, Caceres O, Roder N, Momplaisir F, Cronholm P. Barriers and facilitators to Long-Acting injectable HIV PrEP implementation in primary care since its approval in the united States. JAIDS J Acquir Immune Defic Syndr. 2022:101097."},{"key":"5038_CR27","doi-asserted-by":"crossref","unstructured":"Kolstee J, Wang H, Zimmermann H, Schroeder M, Appiah A, Brown C et al. Design and Methods of the Understanding pre-exposure prophylaxis modalities for HIV prevention in European communities (PROTECT) Survey. medRxiv. 2024:2024.11.04.24316697.","DOI":"10.1101\/2024.11.04.24316697"},{"key":"5038_CR28","doi-asserted-by":"crossref","unstructured":"Wang H, Kolstee J, Gaetani M, Aphami L, Lozano AA, Zimmermann HM, et al. Interest in and preference for long-acting injectable PrEP among men who have sex with men, trans* individuals, and cis-gender heterosexual women: a global systematic review and meta-analysis. JAIDS J Acquir Immune Defic Syndr. 2025. 10.1097.","DOI":"10.1101\/2024.09.25.24314401"},{"issue":"1","key":"5038_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14792772143000003","volume":"12","author":"P Sheeran","year":"2002","unstructured":"Sheeran P. Intention\u2014behavior relations: a conceptual and empirical review. Eur Rev Soc Psychol. 2002;12(1):1\u201336.","journal-title":"Eur Rev Soc Psychol"},{"key":"5038_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1196958","volume":"11","author":"YJ Evers","year":"2023","unstructured":"Evers YJ, Goense CJ, Hoebe CJ, Dukers-Muijrers NH. Newly diagnosed HIV and use of HIV-PrEP among non-western born MSM attending STI clinics in the Netherlands: a large retrospective cohort study. Front Public Health. 2023;11:1196958.","journal-title":"Front Public Health"},{"issue":"4","key":"5038_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s13178-019-00413-0","volume":"17","author":"P Weatherburn","year":"2020","unstructured":"Weatherburn P, Hickson F, Reid DS, Marcus U, Schmidt AJ. European men-who-have-sex-with-men internet survey (EMIS-2017): design and methods. Sex Res Soc Policy. 2020;17(4):543\u201357.","journal-title":"Sex Res Soc Policy"},{"key":"5038_CR32","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s10461-020-03109-4","volume":"25","author":"M Basten","year":"2021","unstructured":"Basten M, den Daas C, Heijne JC, Boyd A, Davidovich U, Rozhnova G, et al. The rhythm of risk: sexual behaviour, PreP use and HIV risk perception between 1999 and 2018 among men who have sex with men in Amsterdam, the Netherlands. AIDS Behav. 2021;25:1800\u20139.","journal-title":"AIDS Behav"},{"issue":"14","key":"5038_CR33","doi-asserted-by":"publisher","first-page":"8829","DOI":"10.3390\/ijerph19148829","volume":"19","author":"H Wang","year":"2022","unstructured":"Wang H, Shobowale O, Den Daas C, Op de Coul E, Bakker B, Radyowijati A, et al. Determinants of PrEP uptake, intention and awareness in the netherlands: a socio-spatial analysis. Int J Environ Res Public Health. 2022;19(14):8829.","journal-title":"Int J Environ Res Public Health"},{"issue":"9637","key":"5038_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(08)60884-3","volume":"372","author":"MH Merson","year":"2008","unstructured":"Merson MH, O\u2019Malley J, Serwadda D, Apisuk C. The history and challenge of HIV prevention. Lancet. 2008;372(9637):475\u201388.","journal-title":"Lancet"},{"key":"5038_CR35","first-page":"40","volume-title":"The Dutch response to HIV","author":"H Hospers","year":"2002","unstructured":"Hospers H, Blom C. HIV prevention activities for gay men in the Netherlands 1983\u201393. In: The Dutch response to HIV. Oxfordshire: Routledge; 2002. p. 40\u201360."},{"key":"5038_CR36","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s10461-016-1565-9","volume":"21","author":"GJ Greene","year":"2017","unstructured":"Greene GJ, Swann G, Fought AJ, Carballo-Di\u00e9guez A, Hope TJ, Kiser PF, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among US men who have sex with men. AIDS Behav. 2017;21:1336\u201349.","journal-title":"AIDS Behav"},{"issue":"1","key":"5038_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32014-8","volume":"13","author":"SA John","year":"2023","unstructured":"John SA, Zapata JP, Dang M, Pleuhs B, O\u2019Neil A, Hirshfield S, et al. Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17\u201324 years old. Sci Rep. 2023;13(1):5116.","journal-title":"Sci Rep"},{"key":"5038_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25319","author":"H Ward","year":"2019","unstructured":"Ward H, Garnett GP, Mayer KH, Dallabetta GA. Maximizing the impact of HIV prevention technologies in sub-Saharan Africa. J Int AIDS Soc. 2019. https:\/\/doi.org\/10.1002\/jia2.25319.","journal-title":"J Int AIDS Soc"},{"issue":"39","key":"5038_CR39","doi-asserted-by":"publisher","first-page":"764","DOI":"10.46234\/ccdcw2020.163","volume":"2","author":"RW Eisinger","year":"2020","unstructured":"Eisinger RW, Fauci AS. Ending the global HIV epidemic begins at the individual National level: an update from the United States. China CDC Wkly. 2020;2(39):764.","journal-title":"China CDC Wkly"},{"key":"5038_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-020-01852-y","volume":"18","author":"KF Ortblad","year":"2020","unstructured":"Ortblad KF, Stekler JD. Hiv self-testing: finding its way in the prevention tool box. BMC Med. 2020;18:1\u20133.","journal-title":"BMC Med"},{"key":"5038_CR41","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s10461-015-1238-0","volume":"20","author":"SA Elsesser","year":"2016","unstructured":"Elsesser SA, Oldenburg CE, Biello KB, Mimiaga MJ, Safren SA, Egan JE, et al. Seasons of risk: anticipated behavior on vacation and interest in episodic antiretroviral pre-exposure prophylaxis (PrEP) among a large National sample of US men who have sex with men (MSM). AIDS Behav. 2016;20:1400\u20137.","journal-title":"AIDS Behav"},{"issue":"5","key":"5038_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/QAI.0000000000000101","volume":"65","author":"HA Pines","year":"2014","unstructured":"Pines HA, Gorbach PM, Weiss RE, Shoptaw S, Landovitz RJ, Javanbakht M, et al. Sexual risk trajectories among MSM in the united states: implications for pre-exposure prophylaxis delivery. JAIDS J Acquir Immune Defic Syndr. 2014;65(5):579\u201386.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"5038_CR43","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s10508-017-1100-8","volume":"47","author":"K Underhill","year":"2018","unstructured":"Underhill K, Guthrie KM, Colleran C, Calabrese SK, Operario D, Mayer KH. Temporal fluctuations in behavior, perceived HIV risk, and willingness to use pre-exposure prophylaxis (PrEP). Arch Sex Behav. 2018;47:2109\u201321.","journal-title":"Arch Sex Behav"},{"issue":"7","key":"5038_CR44","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2468-2667(21)00112-2","volume":"6","author":"BR Bavinton","year":"2021","unstructured":"Bavinton BR, Grulich AE. HIV pre-exposure prophylaxis: scaling up for impact now and in the future. Lancet Public Health. 2021;6(7):e528\u201333.","journal-title":"Lancet Public Health"},{"key":"5038_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2407001.","journal-title":"N Engl J Med"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05038-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05038-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05038-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:32:33Z","timestamp":1784892753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05038-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5038"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05038-0","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"12 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no other competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}